AlphaStocks
4.0
Weak

Cytek Biosciences, Inc. (CTKB)

Health Care / Health Care Equipment

S&P SmallCap 600

$4.48

Below average on several measures. Research carefully.

Weak

Score based on 3 of 5 models — moderate confidence

#843out of 1127 in Health Care

Is Cytek Biosciences, Inc. a Good Investment in 2026?

Cytek Biosciences, Inc. (CTKB) scores 4.0 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating Cytek Biosciences, Inc. as Neutral. However, the Graham model rates it Caution. Cytek Biosciences, Inc. ranks #843 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-17.1Market Cap575.9M

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

3/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Cytek Biosciences, Inc. (CTKB) a good investment?
Based on AlphaStocks' composite analysis, Cytek Biosciences, Inc. (CTKB) scores 4.0 out of 10, earning a Weak rating. This score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Cytek Biosciences, Inc.'s Piotroski F-Score?
Cytek Biosciences, Inc.'s Piotroski F-Score status is Neutral. The raw score is 3/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is CTKB overvalued or undervalued?
A precise fair value estimate is not available for CTKB. Currently unprofitable — fair value estimate not available.
How does CTKB compare to other Health Care stocks?
Cytek Biosciences, Inc. ranks #843 out of 1127 stocks in the Health Care sector, placing it in the top 75% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about CTKB?
AlphaStocks evaluates CTKB using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution. These models are combined into a single composite score of 4.0/10.

Similar Stocks

PARRFTIAZN

Compare CTKB with

CTKB vs PARRCTKB vs FTICTKB vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer